# NCT06162221 (NCT06162221)

> Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06162221
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC
- Interventions: RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805
- Enrollment: 616
- Primary outcome: Adverse events
- Primary outcome: Dose limiting toxicities

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06162221